Psychedelics
Meet the Team Who Want To Develop Psychedelics Without the Hallucinations
Technology Networks – Analytical Cannabis’ sister publication – spoke to the team at Delix Therapeutics' to learn how their drugs can keep the benefits of psychedelics compounds while leaving behind the trip.
Analytical Cannabis Named ‘Unsung Hero’ by NewsGuard
The credibility watchdog praised Analytical Cannabis’ dedication to fact-based reporting of cannabis industry events and relevant scientific research.
Most Psychedelic Drug Users Believe in a Higher Power Following Their Trip, Study Finds
While these psychedelics users did tend to report an increased belief in the paranormal after their trip, superstitious beliefs largely remained unchained.
The Top 10 Cannabis Stories of 2022
Analytical Cannabis rounds up the year’s top cannabis stories, with a particular focus on research and testing.
Awakn Expands Its Ketamine Trial For Alcohol Use Disorder
The first-of-its-kind phase 3 trial will soon begin in the UK to test whether ketamine can help treat patients with alcohol use disorder.
Is Ayahuasca Safe? We Ask a Researcher
Dr. Perkins spoke with Technology Networks – the sister publication of Analytical Cannabis – to provide context on the latest research study and the next steps for the research group.
International Regulatory Developments For Key Psychedelics
Stephen Wright breaks down the lengthy process of getting a psychedelic medicine approved in the US.
Most Ayahuasca Users Vomit, Study Finds
Acute physical health adverse effects were reported by 69.9% of the study's participants.
The Dark Side of Psychedelic Trials
Dr. Markus Roggen, president and chief science officer of Vancouver-based Delic Labs, delves into the less favorable side of psychedelic research.
